Piramal to Acquire Five Janssen Injectables

Published on: 

Piramal entered into an agreement with Janssen Pharmaceuticals to acquire five of the company’s injectable products.

On Oct. 10, 2016, Piramal Enterprises’ Critical Care Division announced that the company has entered into an agreement with Janssen Pharmaceutical to acquire five of Janssen’s injectable anesthesia and pain management products. The company will acquire the five products in an all cash deal for an upfront consideration of $155 million, and up to an additional $20 million.

Piramal will acquire five injectable versions of the following Janssen products:

  • Sublimaze (fentanyl citrate)

  • Sufenta (sufentanil citrate)

  • Rapifen (alfentanil hydrochloride)

  • Dipidolor (piritramide)

  • Hypnomidate (etomidate).

These products are currently marketed in more than 50 countries. Piramal has agreed to acquire the brand names and all related intellectual property associated with the products, including the information on how to make both the APIs and the finished dosage forms.

The potential acquisition does not include the transfer of any manufacturing facilities or employees. As part of the transaction, Janssen will continue to supply finished dosage forms for up to three years and API for up to five years. Janssen will continue to sell the products on behalf of Piramal, until the marketing authorizations or relevant business relations are transferred to Piramal. The transaction is expected to close this week.

Source: Piramal